Search results
Mankind Pharma is one of the Indian leading pharmaceutical companies, and changes the pharma industry by providing world class medications at affordable prices and maintaining quality standards by using state-of-the-art technology for production of high-quality medicines.
Mankind Pharma, is an Indian multinational pharmaceutical and healthcare product company, headquartered in Delhi, India. The company has products in therapeutic areas ranging from antibiotics, to gastrointestinal, cardiovascular, dermal, and erectile dysfunction medications.
Mankind Pharma focuses on a variety of therapeutic segments such as Cardiovascular, Antibiotics, Gastro-intestinal, Anti-allergic, Anti-fungal, Nutritional, NSAIDs, Ortho and Gynaecological. Every day 75 Lacs Indians consume Mankind's cardiac care products.
3 days ago · Mankind Pharma has appointed Barclays and Deutsche Bank to arrange financing for its Rs 13,630 crore acquisition of Bharat Serums & Vaccines. The deal will be partly funded through Rs 4,000 crore in internal accruals and the rest via debt. Mankinds board approved raising ₹7,500 crore in equity and increasing the borrowing limit to ₹12,500 crore.
1 day ago · New Delhi-based pharmaceutical major Mankind Pharma is poised to take pole position in women's health portfolio in the India Pharma Market (IPM) after completing the Rs 13,630 crore deal to ...
Mankind Pharma, Best pharmaceutical company in India, has a wide range of products like Antibiotic, Antifungal, NSAIDs, Gastrointestinal, Anthelmintic, Cardiovascular Dermal, Erectile Dysfunction etc.
5 days ago · Indian drugmaker Mankind Pharma said late on Thursday it would acquire Bharat Serums and Vaccines Ltd in a deal valued at around 136.30 billion rupees ($1.63 billion), including debt.
4 days ago · Mankind Pharma Ltd. has picked Barclays Plc and Deutsche Bank AG to help arrange financing for its proposed 138 billion rupees ($1.6 billion) acquisition of Bharat Serums & Vaccines Ltd ...
5 days ago · This strategic move marks a significant leap for Mankind Pharma, positioning it as a market leader in the Indian women’s health and fertility drug market alongside access to other high entry barrier products in critical care with established complex R&D tech platforms, Mankind Pharma said. Unlisted BSV reported revenues of Rs 1,723 crore in FY24, delivering robust 20% y-o-y growth with adjusted EBITDA margins of 28 per cent. The business has grown at 21 per cent revenue CAGR over the last ...
4 days ago · Mankind Pharma Share Price Today (29 Jul, 2024): Mankind Pharma Stock Price (₹ 2063.00) Live NSE/BSE updates on The Economic Times. Check out why Mankind Pharma share price is up today. Get all details on Mankind Pharma shares news and analysis, Forecasts, Dividend, balance sheet, profit & loss, Quarterly results, annual report information ...
